Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of limb-girdle muscular dystrophy (LGMD), a group of rare genetic disorders marked ...

The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...

This is due to the safety concerns around Elevidys, its one-shot gene therapy for DMD. Last month, Sarepta reported the death of a young patient after treatment with Elevidys. Though this patient ...

In other recent news, Sarepta Therapeutics has been the focus of several analyst updates and regulatory developments concerning its gene therapy, ELEVIDYS, for Duchenne muscular dystrophy (DMD). Wells ...

In other recent news, Sarepta Therapeutics has been the focus of several analyst updates and regulatory developments concerning its gene therapy, ELEVIDYS, for Duchenne muscular dystrophy (DMD).

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene therapy Elevidys in the wake of the death of a patient who received the ...

Sarepta issued a press release disclosing the death of "a young man with Duchenne muscular dystrophy . . . following treatment with ELEVIDYS", Sarepta's Duchenne muscular dystrophy drug ...

The life sciences hedge fund was down 32 percent in the first quarter alone in a generally rough period for much of the ...

Dr. Elkins was recently Head of Development Sciences and Chief Medical Officer at Sarepta Therapeutics supporting the development of ELEVIDYS, the first gene therapy approved for the treatment of ...